EU MDR: Notified Body Clinical Evidence Expectations Could Spell Trouble For Manufacturers
Detailed guidance documents aim to provide clarity on what constitutes “sufficient” clinical evidence under the new EU Medical Device Regulation. But a void remains between the MDR itself and what notified bodies expect, senior regulatory consultant Søren Underbjerg attests.
You may also be interested in...
Manufacturers of high-risk class III medical devices and class IIb active medical devices that administer or remove medicinal products from the human body will be able to access expert panel advice prior to applying for CE-marking under a newly-announced European Medicines Agency pilot scheme.
Yet another EU regulatory organization has stressed the need for action to address MDR capacity problems. According to CAMD, underlying factors and causes of the crisis must be identified.
There are growing fears that the new EU medtech regulations could result in products used for children or rare diseases vanishing from the market. In an interview with Medtech Insight, regulatory expert Tom Melvin explains how these devices can be protected.